Opinion: Canada is long overdue for a national registry of drug company payments to doctors
It is past time for Canada to create a national registry of payments that pharmaceutical and medical device companies make to health care providers.
Ontario recently took a historic step as the first province in Canada to introduce legislation that would shine a light on interactions between drug companies and prescribers. The use of the term “historic” here is not hyperbole, since the extent of payments by the pharmaceutical industry to individual physicians in Canada has never been known.
Other countries, such as the United States and France, have been making such information public for a few years now. But Ontario’s bill would provide a wider scope of transparency by including
